Catalyst Biosciences (CBIO) Lifted to Sell at ValuEngine

Catalyst Biosciences (NASDAQ:CBIO) was upgraded by ValuEngine from a “strong sell” rating to a “sell” rating in a research report issued to clients and investors on Friday.

Other equities analysts have also issued research reports about the company. B. Riley set a $19.00 price objective on Catalyst Biosciences and gave the company a “buy” rating in a research note on Monday, December 18th. Zacks Investment Research upgraded Catalyst Biosciences from a “hold” rating to a “buy” rating and set a $5.25 price objective for the company in a research note on Wednesday, November 8th. One analyst has rated the stock with a sell rating and four have issued a buy rating to the company. Catalyst Biosciences presently has a consensus rating of “Buy” and a consensus target price of $13.75.

Catalyst Biosciences (NASDAQ:CBIO) opened at $25.27 on Friday. Catalyst Biosciences has a 52 week low of $3.11 and a 52 week high of $27.01.

Catalyst Biosciences (NASDAQ:CBIO) last released its quarterly earnings data on Thursday, November 2nd. The biopharmaceutical company reported ($1.34) earnings per share for the quarter. The company had revenue of $0.32 million for the quarter. Catalyst Biosciences had a negative net margin of 2,438.50% and a negative return on equity of 91.67%. research analysts expect that Catalyst Biosciences will post -7.35 EPS for the current year.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in CBIO. Virtu KCG Holdings LLC purchased a new position in shares of Catalyst Biosciences during the 2nd quarter valued at about $103,000. Bank of New York Mellon Corp purchased a new position in shares of Catalyst Biosciences during the 2nd quarter valued at about $107,000. Zacks Investment Management purchased a new position in shares of Catalyst Biosciences during the 2nd quarter valued at about $147,000. Vanguard Group Inc. raised its stake in shares of Catalyst Biosciences by 294.1% during the 2nd quarter. Vanguard Group Inc. now owns 43,714 shares of the biopharmaceutical company’s stock valued at $204,000 after buying an additional 32,621 shares during the last quarter. Finally, Dimensional Fund Advisors LP purchased a new position in shares of Catalyst Biosciences during the 2nd quarter valued at about $372,000. Institutional investors and hedge funds own 22.96% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This report was first reported by Community Financial News and is the property of of Community Financial News. If you are viewing this report on another domain, it was copied illegally and reposted in violation of U.S. & international copyright law. The correct version of this report can be accessed at https://www.com-unik.info/2018/02/04/catalyst-biosciences-cbio-lifted-to-sell-at-valuengine.html.

Catalyst Biosciences Company Profile

Catalyst Biosciences, Inc, formerly Targacept, Inc, is a clinical-stage biopharmaceutical company. The Company is focused on creating and developing medicines to address serious medical conditions. The Company focuses its product development efforts in the fields of hemostasis, including the treatment of hemophilia and surgical bleeding, and inflammation, including prevention of delayed graft function (DGF) in renal transplants and the treatment of dry age-related macular degeneration (dry AMD), a condition that can cause visual impairment or blindness.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Catalyst Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit